Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Issue 2 (18th December 2022)

• Record Type: Journal Article
• Authors: Yu, Jacky K.; Wong, William W. L.; Keepanasseril, Arun; Iorio, Alfonso; Edginton, Andrea N.
• Is Part Of: Haemophilia. Volume 29:Issue 2(2023)
• Page Start: 488
• Page End: 497
• Publication Date: 2022-12-18
• Subjects: economic evaluation -- emicizumab -- haemophilia A; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.14723
• Languages: English
• ISSNs: 1351-8216

Abstract

Abstract: Introduction: EHL FVIII products and emicizumab provide clinicians with other prophylactic options for treating hemophilia A, however, it is unclear if emicizumab is a cost‐saving option. The objective of this study is to estimate the health and economic effects of using prophylactic EHL FVIII, SHL FVIII, and emicizumab in severe haemophilia A patients. Materials and Methods: A state‐transition Markov model evaluated the cost‐effectiveness of prophylactic SHL FVIII, EHL FVIII, and emicizumab in a cohort of 2‐year‐old male patients over a lifetime horizon in the form of a cost‐utility analysis using a Canadian provincial ministry of health payer perspective. The transition probabilities, costs, and utilities were obtained from literature and the Canadian Bleeding Disorders Registry. Probabilistic sensitivity and scenario analyses were performed to test the robustness of the model. Results: The base‐case analysis, over a lifetime horizon, resulted in a total cost and utilities per person for SHL FVIII, EHL FVIII, and emicizumab of $27.2 million (M), $36.7 M, and $26.2 M, respectively, and 31.30, 31.16, and 31.61 quality‐adjusted life years, respectively. Emicizumab treatment resulted in 29 and 16 less bleeds in a lifetime compared to SHL FVIII and EHL FVIII, respectively. Probabilistic sensitivity analysis showed that emicizumab was cost‐saving 100% of the time compared to SHL FVIII and EHL FVIII. Conclusion: The cost‐utility analysis showed that emicizumab is more effective and may be less costly than FVIII for Canadian haemophilia A patients, conditional on drug cost assumptions. Our model indicates that emicizumab may be a potentially favourable treatment option for minimising healthcare costs and providing higher effectiveness.